TMCnet News
TyRx Pharma, Inc. to Present at The Seventh Annual Needham & Co., LLC Biotechnology & Medical Technology Conference(Marketwire Via Acquire Media NewsEdge) MONMOUTH JUNCTION, NJ, June 5 / MARKET WIRE/ -- TyRx Pharma, Inc., a leader in the commercialization of implantable combination drug/device products, announced today that William Edelman, the company's chief executive officer, will present at The Seventh Annual Needham & Co., LLC Biotechnology & Medical Technology Conference on Wednesday, June 11, 2008 at 8:30 am/ (ET) at the New York Palace Hotel. TyRx's announced on May 14th, the first commercial implant of the AIGISRX(TM) Anti-Bacterial Envelope in a CRMD procedure conducted at St. Luke's Episcopal Hospital of the Texas Heart Institute in Houston following its FDA clearance earlier this year. On February 27th, 2008, TyRx announced that the Company raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. About TyRx Pharma, Inc. TyRx Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products utilizing novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TyRx has exclusively licensed from Baylor College of Medicine and The associated technologies to address the problem of postsurgical nosocomial infection. TyRx is deploying its capabilities across a broad range of combination implantable drug/devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TyRx is positioned to be an innovative applications leader in the space. For more information, please visit www.tyrxpharma.com. Contact: Bill Edelman CEO TyRx Pharma, Inc. Office: 732-246-8676 Direct: 732-964-1101 Cell: 617-759-5451Email Contact Copyright ? 2008 Marketwire |